Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Self-sacrificing ants highlight the unity of their colony, say researchers - 2Americans generally like wolves − except when we’re reminded of our politics
- 36 Pet Sitting Administrations for Your Cherished Pets
- 4Wedding trip Objections in the US
- 5Israeli strikes in Gaza kill 25 people, Hamas health authority says
- Exemplary Fragrances: A Manual for Notorious Scents
- Heartfelt Objections to Visit with Your Adored One
- Ukraine apologizes to Finland for crashed drones
- The Forgotten BMW Coupe That Turned a 5 Series Into Something Far More Exotic
- What loving-kindness meditation is and how to practice it in the new year
- Director Emerald Fennell explains why "Wuthering Heights" has quotation marks around the title
- Oil Tanker Carrying Iraqi Cargo Seen Transiting Strait of Hormuz
- An Investigate of 6 Creative Specialty Mixed drinks
- Iran’s Crown Prince Reza Pahlavi backs protests: Join your fellow citizens in the streets
